Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study tests the assumption that the bioavailability of alprazolam from a new sublingual formulation is the same as that from sublingual formulation expected to be used commercially in Brazil.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| alprazolam sublingual tablet reference | Active Comparator |
| |
| alprazolam sublingual tablet test | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| alprazolam sublingual tablet commercial | Drug | 0.5 mg sublingual tablet, single dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| Alprazolam bioavailability assessed as area under the concentration-time curve (AUC) and maximum concentration (Cmax) | 11 days |
| Measure | Description | Time Frame |
|---|---|---|
| Alprazolam time of maximum concentration (Tmax) and half life | 11 days | |
| Adverse events, clinical laboratory tests, vital signs | 11 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
Not provided
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| alprazolam sublingual tablet test | Drug | 0.5 mg tablet, single dose |
|